VTRS news

• Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia

  PRNewsWire · Oct 16, 2026
• Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

  Business Wire · Oct 12, 2026
• Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

  Zacks Investment Research · Oct 9, 2026
• SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)

  Newsfile Corp · Oct 8, 2026
• Why Pacira BioSciences Skyrocketed Today

  Fool - Investing News · Oct 8, 2026
• Viatris to Buy Pacira BioSciences for $1.65 Billion

  WSJ · Oct 8, 2026
• Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

  PRNewsWire · Oct 8, 2026
• VTRS vs. AVTR: Which Stock Is the Better Value Option?

  Zacks Investment Research · Oct 6, 2026
• Should Value Investors Buy Viatris (VTRS) Stock?

  Zacks Investment Research · Oct 6, 2026
• Viatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy?

  Zacks Investment Research · Oct 5, 2026
• Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026

  PRNewsWire · Oct 5, 2026
• Why Viatris (VTRS) is a Top Value Stock for the Long-Term

  Zacks Investment Research · Oct 1, 2026
• Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year

  GuruFocus · Sep 29, 2026
• Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year

  PRNewsWire · Sep 29, 2026
• Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields

  Benzinga · Sep 23, 2026
• Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome

  PRNewsWire · Sep 16, 2026
• Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive

  Seeking Alpha · Sep 9, 2026
• Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?

  Zacks Investment Research · Sep 9, 2026
• Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris

  Proactive Investors · Aug 28, 2026
• 3 Generic Drug Stocks to Watch Amid Improving Industry Trends

  Zacks Investment Research · Aug 27, 2026
• Here's Why Viatris (VTRS) is a Strong Value Stock

  Zacks Investment Research · Aug 18, 2026
• Viatris Inc. (VTRS) Q2 2026 Earnings Call Transcript

  Seeking Alpha · Aug 6, 2026
• Viatris Inc (VTRS) Shares Fall 7.6% -- GF Value Says Still Overvalued

  GuruFocus · Aug 6, 2026
• Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook

  Benzinga · Aug 6, 2026
• VTRS Q2 Earnings Beat, Revenues Rise 5% as Greater China Sales Jump

  Zacks Investment Research · Aug 6, 2026
• Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics

  Zacks Investment Research · Aug 6, 2026
• Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates

  Zacks Investment Research · Aug 6, 2026
• Viatris Reports Second-Quarter 2026 Financial Results

  PRNewsWire · Aug 6, 2026
• Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

  Zacks Investment Research · Aug 5, 2026
• Viatris Gears Up to Report Q2 Earnings: What's in the Cards?

  Zacks Investment Research · Aug 4, 2026

Sentiment classified by AI from the headline (green positive, red negative). Links open the publisher.